A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
A phase 1/2 trial of TAK-188 in advanced solid tumours, run by Takeda, now recruiting.
Overview
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors is a phase 1/2 interventional study registered as NCT07205718 by Takeda, with 223 participants planned, started 2025-11-19 and due to reach its primary completion in 2028-12-26. Interventions recorded: TAK-188.
Similar pages
not linked directly; found by shared links- TrialA Study of TAK-505 in Adults With Solid Tumors
Shares Takeda, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Shares Takeda and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Takeda and the tag pipeline.
- TrialA Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Shares Takeda and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.